How much has JNJ stock risen this year?

The stock has risen about 25% year to date and about 66% over the past year.

Is JNJ better than AbbVie and Pfizer?

JNJ has a more diversified and stable portfolio, making it less affected by patent expirations compared to some peers.

Is Johnson & Johnson (JNJ) a Buy Before July 15 Earnings?

Ahead of Johnson & Johnson's July 15 earnings release, analysts see a clear investment case as the stock has risen 25% YTD and 66% over the past year. The article reviews the company's strong fundamentals.

July 13, 2026

2 min read

Source: 24/7 Wall St.

Key Numbers

ytd return

25%

one year return

66%

earnings date

July 15

According to an analysis by 24/7 Wall St., Johnson & Johnson (NYSE: JNJ) is one of the easiest healthcare stocks to evaluate ahead of its upcoming earnings release on July 15. The stock has risen nearly 25% year to date and about 66% over the past year, reflecting market confidence in the company's fundamentals.

Recommendation Change

The report does not indicate a specific analyst rating change, but focuses on the stock's strong performance and the upcoming earnings as a catalyst.

Analyst Rationale

Analysts see a clear case for JNJ: the company has a diversified portfolio of pharmaceuticals and medical devices, with stable cash flows. Its consistent dividend payments make it attractive for long-term investors.

Context

In the healthcare sector, JNJ outperforms many peers like AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) in terms of stability and growth. While some companies face patent cliff challenges, JNJ benefits from product diversification.

What to Conclude

JNJ offers a balanced investment opportunity, but past performance does not guarantee future results. Investors are advised to assess risks before making decisions.

Frequently Asked Questions

The company reports earnings on July 15.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.